Chloe Ramirez
The monkeypox vaccine, a critical tool in combating the spread of the virus, is primarily manufactured by Bavarian Nordic, a Danish biotechnology company. Their vaccine, known as JYNNEOS (also called Imvamune or Imvanex in some regions), is a third-generation, non-replicating smallpox and monkeypox vaccine approved by the U.S. Food and Drug Administration (FDA) and other regulatory bodies worldwide. Developed as a safer alternative to older smallpox vaccines, JYNNEOS has gained prominence due to the increasing global concern over monkeypox outbreaks. Bavarian Nordic has scaled up production to meet the rising demand, collaborating with governments and health organizations to ensure widespread availability. Additionally, other manufacturers and research institutions are exploring the development of alternative vaccines, but as of now, Bavarian Nordic remains the primary producer of the approved monkeypox vaccine.
| Characteristics | Values |
|---|---|
| Manufacturer | Bavarian Nordic |
| Vaccine Name | JYNNEOS (also known as Imvamune or Imvanex) |
| Type | Live, non-replicating vaccinia virus (Modified Vaccinia Ankara - MVA) |
| Approval Status | Approved by the U.S. FDA, EMA, and other regulatory agencies |
| Indication | Prevention of smallpox and monkeypox in individuals 18 years and older |
| Dosage | Two doses administered subcutaneously, 4 weeks apart |
| Storage | Stored at 2°C to 8°C (36°F to 46°F) |
| Shelf Life | 36 months when stored properly |
| Efficacy | Demonstrated high efficacy in clinical trials and real-world use |
| Side Effects | Generally mild to moderate, including pain at injection site, fatigue, headache, and muscle pain |
| Availability | Distributed globally, with increased production to meet demand during outbreaks |
| Notable Use | Widely used during the 2022 monkeypox outbreak |
| Manufacturer Location | Headquartered in Denmark, with production facilities in Denmark and Germany |
| Additional Notes | Also used for smallpox vaccination due to its safety profile compared to older vaccinia-based vaccines |
Explore related products
What You'll Learn
- Bavarian Nordic: Primary manufacturer of the Jynneos vaccine, approved for monkeypox prevention
- Vaccine Types: Jynneos (non-replicating) and ACAM2000 (replicating) are key monkeypox vaccines
- Global Supply: Limited Jynneos doses; distribution challenges during 2022 outbreak
- Approval Process: Jynneos approved by FDA in 2019 for smallpox and monkeypox
- Alternative Manufacturers: Efforts to expand production with partnerships and new facilities
Bavarian Nordic: Primary manufacturer of the Jynneos vaccine, approved for monkeypox prevention
Bavarian Nordic, a Danish biotechnology company, stands as the primary manufacturer of the Jynneos vaccine, the only vaccine currently approved by the U.S. Food and Drug Administration (FDA) for the prevention of monkeypox. Unlike older vaccines derived from the vaccinia virus, Jynneos is a non-replicating vaccine, meaning it cannot multiply in the human body. This design significantly reduces the risk of severe side effects, making it a safer option for individuals with weakened immune systems, including those with HIV. The vaccine’s approval in 2019 for smallpox and monkeypox in adults 18 years and older marked a critical advancement in preparedness for orthopoxvirus outbreaks.
Administered in a two-dose series, Jynneos requires an initial injection followed by a second dose 28 days later for maximum efficacy. Each dose delivers 0.5 mL of the vaccine, administered subcutaneously (just under the skin). While the vaccine is most effective when both doses are completed, even a single dose can provide partial protection, a crucial consideration during supply shortages. The CDC recommends vaccination for individuals at high risk of exposure, including healthcare workers handling orthopoxviruses, laboratory personnel, and those with confirmed or presumed exposure to monkeypox.
One of Bavarian Nordic’s challenges has been scaling production to meet global demand during the 2022 monkeypox outbreak. The company has partnered with governments and organizations worldwide to expand manufacturing capacity, including a collaboration with the U.S. government to fill and finish doses at a Michigan facility. Despite these efforts, distribution bottlenecks have persisted, highlighting the complexities of rapidly responding to public health emergencies.
Comparatively, Jynneos offers advantages over older vaccines like ACAM2000, which carries risks of serious adverse reactions, including myocarditis and vaccinia infection. Its safety profile makes Jynneos the preferred choice for broader populations, including pregnant individuals and those with atopic dermatitis. However, it’s essential to note that Jynneos is not a one-size-fits-all solution; its efficacy in children under 18 remains under study, and it is not recommended for those with severe allergies to vaccine components.
For practical implementation, healthcare providers should ensure proper storage of Jynneos at temperatures between -15°C and -25°C until thawed for use. Once thawed, the vaccine remains stable in a refrigerator for up to 8 weeks. Patients should be monitored for 15 minutes post-vaccination for rare allergic reactions. As monkeypox continues to circulate, Bavarian Nordic’s role in producing Jynneos underscores the importance of investing in vaccine infrastructure to address both current and future threats.
Understanding Post-Vaccination Discomfort in Infants: When and Why It Happens
You may want to see also
Explore related products
$99.99 $146.98
Vaccine Types: Jynneos (non-replicating) and ACAM2000 (replicating) are key monkeypox vaccines
The monkeypox vaccine landscape is dominated by two key players: Jynneos and ACAM2000. These vaccines, though both designed to protect against monkeypox, differ fundamentally in their mechanisms and administration. Understanding these differences is crucial for informed decision-making, especially as public health strategies evolve.
Jynneos, manufactured by Bavarian Nordic, is a non-replicating vaccine. This means it contains a modified, non-infectious form of the vaccinia virus, a cousin of the monkeypox virus. This design makes Jynneos safer for individuals with weakened immune systems, pregnant women, and those with certain skin conditions, as it cannot cause disease in the vaccinated individual. The vaccine is administered in two subcutaneous doses, four weeks apart, and is approved for individuals aged 18 and older. Its side effects are generally mild, including pain at the injection site, fatigue, and headache.
ACAM2000, produced by Emergent BioSolutions, takes a different approach. It is a replicating vaccine, containing a live, attenuated (weakened) vaccinia virus. While highly effective, this live virus can cause more significant side effects, including a localized skin lesion at the vaccination site that requires careful management to prevent accidental spread. ACAM2000 is administered via a unique scarification method, where the vaccine is delivered through multiple pricks into the skin's surface. This method, while effective, requires specific training for healthcare providers. Due to its potential risks, ACAM2000 is generally reserved for healthy individuals aged 18 to 49 who are at high risk of exposure to monkeypox.
The choice between Jynneos and ACAM2000 hinges on individual health status and risk factors. Jynneos, with its favorable safety profile, is the preferred option for most individuals, especially those with compromised immune systems. ACAM2000, while highly effective, is a more specialized tool, best suited for healthy individuals in high-risk settings.
The availability and distribution of these vaccines are constantly evolving, influenced by global supply chains and public health priorities. Staying informed about local guidelines and recommendations is essential for accessing the most appropriate vaccine.
Ultimately, the development and deployment of these two distinct monkeypox vaccines highlight the importance of scientific innovation and tailored public health strategies in combating emerging infectious diseases.
Live Influenza Vaccines: Identifying the Right Option for You
You may want to see also
Explore related products
Global Supply: Limited Jynneos doses; distribution challenges during 2022 outbreak
The 2022 monkeypox outbreak exposed a critical vulnerability: a severe shortage of Jynneos, the preferred vaccine for prevention. Manufactured by Bavarian Nordic, a Danish biotechnology company, Jynneos was in high demand due to its safety profile, including approval for immunocompromised individuals and those with a history of skin conditions. However, Bavarian Nordic's production capacity was limited, with only a few million doses available globally at the outset of the outbreak. This scarcity forced public health officials to ration doses, prioritizing high-risk groups such as men who have sex with men, healthcare workers, and those with known exposure.
The distribution of Jynneos was further complicated by logistical hurdles. The vaccine requires ultra-cold storage, a challenge for many low- and middle-income countries with limited infrastructure. Additionally, the two-dose regimen, administered 28 days apart, strained already overburdened healthcare systems. To stretch limited supplies, some countries adopted a fractional dosing strategy, administering one-fifth of the standard dose intradermally. While this approach showed promise in early studies, it required careful training and monitoring to ensure proper administration and efficacy.
The global response to the monkeypox outbreak highlighted the need for equitable vaccine distribution. Wealthier nations, such as the United States and European countries, secured the majority of available Jynneos doses, leaving many African countries, where monkeypox is endemic, with little access. This disparity underscored the ongoing challenges in global health equity, reminiscent of the COVID-19 vaccine rollout. International organizations, including the World Health Organization (WHO) and Gavi, the Vaccine Alliance, worked to address these imbalances, but their efforts were hampered by limited supply and logistical constraints.
Practical considerations for Jynneos administration further complicated its rollout. The vaccine is contraindicated in individuals with a history of severe allergic reactions to any component of the vaccine. Pregnant and breastfeeding individuals were advised to consult their healthcare provider before vaccination, as data on safety in these populations was limited. For those receiving the vaccine, common side effects included pain at the injection site, fatigue, and headache, typically resolving within a few days. Public health campaigns emphasized the importance of completing the two-dose series for optimal protection, even as supply constraints delayed second doses in some regions.
In conclusion, the 2022 monkeypox outbreak revealed the fragility of global vaccine supply chains and the urgent need for scalable manufacturing and equitable distribution strategies. Bavarian Nordic's role as the sole manufacturer of Jynneos underscored the risks of relying on a single producer for critical vaccines. Moving forward, investments in diversified production capacity, innovative distribution methods, and global cooperation will be essential to prevent future shortages and ensure that all populations have access to life-saving vaccines.
Tennessee Vaccine Eligibility: Who Qualifies for COVID-19 Shots Now?
You may want to see also
Explore related products
Approval Process: Jynneos approved by FDA in 2019 for smallpox and monkeypox
The Jynneos vaccine, developed by Bavarian Nordic, stands as a pivotal tool in the fight against both smallpox and monkeypox. Its approval by the U.S. Food and Drug Administration (FDA) in 2019 marked a significant milestone in public health preparedness. Unlike older smallpox vaccines, which used live vaccinia virus and carried risks of severe side effects, Jynneos employs a modified vaccinia Ankara (MVA) virus that does not replicate in human cells, making it safer for immunocompromised individuals. This innovation addresses a critical gap in vaccine accessibility, ensuring protection for populations previously excluded from vaccination campaigns.
The FDA’s approval process for Jynneos was rigorous, involving extensive clinical trials to evaluate safety, immunogenicity, and efficacy. Studies demonstrated that the vaccine effectively induced neutralizing antibodies against both smallpox and monkeypox viruses. The recommended regimen consists of two subcutaneous doses administered 28 days apart, with full immunity typically achieved within two weeks of the second dose. Notably, Jynneos is approved for individuals aged 18 years and older, including those at high risk of adverse reactions to traditional smallpox vaccines. This approval underscores the FDA’s commitment to modernizing vaccine technology while prioritizing safety and efficacy.
Comparatively, Jynneos’s approval process highlights the evolution of regulatory frameworks in response to emerging threats. While smallpox has been eradicated, the rise of monkeypox cases globally necessitated a dual-purpose vaccine. Bavarian Nordic’s collaboration with governments and health agencies expedited development and approval, showcasing the importance of public-private partnerships in pandemic preparedness. Unlike emergency use authorizations, Jynneos’s full FDA approval provides robust evidence of its long-term safety and efficacy, fostering public trust in vaccination efforts.
For healthcare providers, understanding Jynneos’s administration and storage is crucial. The vaccine should be stored frozen at -15°C to -25°C until ready for use, then thawed and diluted with the provided diluent. Once reconstituted, it remains stable for up to 8 hours at room temperature. Providers must also screen patients for contraindications, such as severe allergies to vaccine components. Practical tips include educating recipients about potential side effects, such as injection site pain, fatigue, and headache, which are generally mild and resolve within a few days.
In conclusion, Jynneos’s FDA approval in 2019 represents a triumph of scientific innovation and regulatory diligence. Its unique design and broad applicability make it a cornerstone of global efforts to combat smallpox and monkeypox. As outbreaks continue to emerge, this vaccine serves as a testament to the power of proactive public health measures, offering a safer, more inclusive solution for disease prevention.
Essential Vaccines Today: Prioritizing Health in a Changing World
You may want to see also
Explore related products
Alternative Manufacturers: Efforts to expand production with partnerships and new facilities
The global demand for monkeypox vaccines has spurred a race to expand production, with alternative manufacturers stepping in to bridge the gap. One notable example is the partnership between Bavarian Nordic, the primary producer of the Jynneos vaccine, and Grand River Aseptic Manufacturing (GRAM) in the United States. This collaboration leverages GRAM’s fill-and-finish capabilities to increase the supply of vialed vaccines, a critical step in ensuring doses reach those most at risk. By focusing on this specific stage of production, the partnership demonstrates how targeted interventions can significantly boost output without requiring a complete overhaul of manufacturing processes.
Analyzing the broader landscape, the World Health Organization (WHO) has encouraged technology transfer agreements to enable manufacturers in low- and middle-income countries to produce monkeypox vaccines. For instance, the Serum Institute of India, known for its role in COVID-19 vaccine production, has expressed interest in manufacturing monkeypox vaccines. Such initiatives not only address immediate supply shortages but also build long-term capacity in regions historically underserved by global health systems. This approach aligns with the WHO’s strategy to decentralize vaccine production and reduce dependency on a handful of manufacturers.
Instructively, expanding production requires more than just partnerships; it demands investment in new facilities and infrastructure. Take the case of Denmark-based Bavarian Nordic, which received funding from the U.S. government to establish a new manufacturing site in the United States. This facility is expected to double the company’s production capacity by 2025, ensuring a steady supply of the Jynneos vaccine. For organizations looking to replicate this model, a key takeaway is to prioritize scalability in facility design, incorporating modular systems that can adapt to evolving demand.
Persuasively, the urgency of the monkeypox outbreak highlights the need for proactive measures to prevent future shortages. Governments and private entities must incentivize manufacturers to diversify their portfolios and invest in vaccine production for emerging diseases. For example, offering advance purchase agreements or subsidies for facility upgrades can mitigate financial risks and encourage participation. Without such interventions, the world risks repeating the inequities seen during the COVID-19 pandemic, where wealthier nations secured the majority of doses.
Comparatively, the monkeypox vaccine production efforts differ from those of COVID-19 in scale and complexity. While COVID-19 required the rapid development and mass production of entirely new vaccines, monkeypox relies on existing smallpox vaccines like Jynneos and ACAM2000. However, the challenge lies in scaling up production of these vaccines, which have historically been manufactured in limited quantities. This distinction underscores the importance of maintaining a flexible manufacturing ecosystem capable of responding to both novel and re-emerging threats.
Descriptively, the process of expanding vaccine production involves meticulous planning and coordination. From securing raw materials to ensuring quality control, each step is critical. For instance, the Jynneos vaccine requires a live virus that must be cultured under strict biosafety conditions, followed by purification and formulation into doses. New manufacturers must adhere to these protocols while optimizing efficiency. Practical tips for facilities include implementing real-time monitoring systems to track production metrics and training staff on specialized equipment to minimize errors. By addressing these details, alternative manufacturers can play a pivotal role in ending the monkeypox outbreak and safeguarding global health.
Feline Immunodeficiency Virus Vaccine: Current Availability and Market Status
You may want to see also
Frequently asked questions
The primary manufacturer of the monkeypox vaccine is Bavarian Nordic, a Danish biotechnology company. Their vaccine, Jynneos (also known as Imvanex or Imvamune in other regions), is approved for use against monkeypox.
While Bavarian Nordic is the main producer, historically, Emergent BioSolutions was involved in manufacturing the ACAM2000 vaccine, which is also approved for smallpox and can be used off-label for monkeypox. However, Jynneos is the preferred vaccine due to its safer profile.
The Jynneos vaccine is primarily manufactured by Bavarian Nordic in Denmark, but distribution and supply agreements may involve partnerships with other countries or organizations to meet global demand during outbreaks.
The older smallpox vaccine, ACAM2000, was developed by the U.S. government and is manufactured by Emergent BioSolutions. It is not specifically a monkeypox vaccine but has been used off-label for prevention due to its cross-protection against orthopoxviruses.
